证券代码：600056 证券简称：中国医药 公告编号：临 2026-007 号 中国医药健康产业股份有限公司 关于召开购买资产有关事项投资者说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）会议召开地点：上证路演中心 （三）会议召开方式：视频和网络互动 三、 参加人员 公司董事长/总经理、总会计师及董事会秘书（如有特殊情况， 参会人员可 能进行调整）。 投资者可于 2026 年 1 月 22 日（星期四）至 1 月 27 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 meheco600056@meheco.gt.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 中国医药健康产业股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日发布关于购买资产的公告，为便于广大投资者更全面深入地了解本次交易的相 关情况，公司计划于 2026 年 1 月 28 日（星期三）15:00-16:00 举行关于购买资 产有关事项的投资者说明会 ...

证券代码：600056 证券简称：中国医药 公告编号：临2026-006号 中国医药健康产业股份有限公司 关于回复购买资产有关事项监管工作函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别风险提示： 1.标的公司业绩大幅下滑及CRO业务（即研发服务业务，下同）萎缩风险： 标的公司所处的CRO行业属于充分竞争行业，行业存在竞争加剧的风险,从而对 其CRO业务带来不利影响。2025年标的公司净利润下降75.99%，其中CRO业务 收入同比下滑46.44%，新签订单金额同比减少30.81%，可能因CRO业务萎缩造 成其业绩进一步下滑风险。 2.技术转让业务可持续性风险：2025年标的公司技术转让业务毛利占比超过 85%，对技术转让业务的利润依赖度较高。标的公司有部分存量自研项目仍在推 进中，存在因技术或临床等原因造成研发进度延迟、上市受阻或上市后收益不及 预期等不确定性情况，同时其技术转让业务能否实现转让存在不确定性，未来可 能存在可持续性风险，从而对其盈利能力造成不利影响。 3.交易估值相对较高及商誉减值风险：本次交易 ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包（CRO）行 业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成(300759.SZ)、泰 格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业(603456.SH)、皓元医药 (688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技(300725.SZ)等。 本文核心数据：CRO产业市场规模 行业概况 2、CRO行业产业链剖析 中国 CRO 产业链贯穿药品全生命周期，可以分为三个阶段。研发阶段CRO，含临床前药物发现、化合物合 成等基础研发与临床阶段试验等;生产阶段CMO/CDMO，覆盖化学原料药、生物药、化学药制剂等不同类型 药物的生产环节;销售阶段CSO，以渠道管理为核心，配套推广营销与市场监测，服务企业、科研机构、医 1、CRO的定义 合同研究组织 (Contract Research Organization, CRO) 是指 ...

Core Insights - In November 2025, China's import volume of medicinal materials and pharmaceuticals was 24,400 tons, representing a year-on-year decrease of 13.1% [1] - The import value for the same period was $4.111 billion, showing a slight decline of 0.2% year-on-year [1] - Conversely, the export volume of medicinal materials and pharmaceuticals reached 160,000 tons, marking a year-on-year increase of 8.6% [1] - The export value was $2.374 billion, reflecting a year-on-year growth of 7.8% [1] Import and Export Analysis - The decline in import volume and value indicates potential challenges in the domestic market for medicinal materials and pharmaceuticals [1] - The increase in export volume and value suggests a growing demand for Chinese medicinal products in international markets [1] - The contrasting trends in imports and exports may highlight shifts in supply chain dynamics and market opportunities for stakeholders in the industry [1]

近日，中国医药（600056）发布公告称，公司下属全资子公司天方药业（600253）有限公司收到国家药 品监督管理局核准签发的两份布洛芬片《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一 致性评价。 布洛芬片主要用于缓解轻至中度疼痛及发热，最早由英国BootsInc研制，1974年在美国上市。截至公告 披露日，布洛芬片的一致性评价累计研发投入约为889万元人民币。 根据市场情况，2024年中国三大终端六大市场该药品销售额约为1.13亿元，2025年前三季度销售额约为 0.69亿元，而公司该药品2025年销售额约为192万元（未经审计）。 ...

Policy Developments - The National Healthcare Security Administration (NHSA) encourages regions with conditions to build global trading platforms for innovative Chinese pharmaceuticals, aiming to facilitate the export of Chinese medical products to Southeast Asia, Central Asia, and other countries [2] Drug and Medical Device Approvals - China Medical (600056.SH) announced that its subsidiary Tianfang Pharmaceutical's ibuprofen tablets have passed the consistency evaluation for generic drugs, which will enhance the product's market competitiveness [4] - Sihuan Pharmaceutical announced that its subsidiary has received approval for six new specifications of its polylactic acid facial filler, further expanding its market presence in the regenerative aesthetic product sector [5] Capital Markets - Qingfeng Biotech (Guangzhou) completed a Pre-A round financing of several tens of millions, led by Baiyun Fund, to accelerate AI and laboratory automation development [7] - Zhongsheng Pharmaceutical (002317.SZ) signed a licensing agreement with Qilu Pharmaceutical for the production and commercialization of RAY1225 injection, with total payments expected to reach RMB 100 million [8] Industry Events - The NHSA signed agreements with 79 hospitals to conduct pilot evaluations of real-world comprehensive value assessments for medical insurance, aiming to enhance the quality and efficiency of the healthcare system [10] - Aipeng Medical and the Shenzhen Institute of Advanced Technology established a "Brain-Computer Interface" innovation consortium to focus on non-invasive brain neuroregulation technology [12] - Novo Nordisk's new CEO emphasized that future business expansions will focus on the core needs of diabetes and obesity patients, indicating a strategic shift towards patient-centered approaches [13] Market Trends - Recent reports indicate significant price reductions for weight loss drugs, with prices for Novo Nordisk's products dropping nearly 50% and some specifications of another drug decreasing by around 80%, leading to substantial savings for patients [16]

Group 1 - The stock price of China Medical (600056) closed at 10.6 yuan on January 16, 2026, down 2.03% from 10.82 yuan the previous week, with a market cap of 15.856 billion yuan, ranking 6th in the pharmaceutical commercial sector and 1330th in the A-share market [1] - The company announced that it will hold the 2024 annual general meeting on May 16, 2025, to review the issuance of corporate bonds and short-term financing bills, and has received approval from the China Securities Regulatory Commission to issue bonds totaling no more than 2 billion yuan [1][3] - The approval for bond issuance is valid for 24 months from the date of registration, allowing the company to issue in tranches during this period [1] Group 2 - The wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the Ibuprofen tablet, which has passed the consistency evaluation of generic drug quality and efficacy [2] - The sales revenue for Ibuprofen tablets in China is estimated to be approximately 113 million yuan in 2024, with the company's sales expected to be around 1.92 million yuan in 2025 [2] - Passing the consistency evaluation is expected to enhance the product's market competitiveness, although future sales remain uncertain [2]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-005 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份布洛芬片（以下简称"该药品"）《药品 补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。现将有关情 况公告如下： 一、通知书基本信息 药品名称：布洛芬片 受理号：CYHB2450548、CYHB2450549 通知书编号：2026B00077、2026B00076 剂型：片剂 规格：0.2g、0.1g 注册分类：化学药品 上市许可持有人：天方药业有限公司 中国医药健康产业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 品进口上市。 （二）国家药监局于 2024 年 11 月受理该药品的一致性评价申请。 （三）截至本公告披露日，该药品一致性评价累计研发投入约为 889 万元人 民币（未经审计）。 （四）药品市场情况 ...

Group 1 - The company, Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received approval from the National Medical Products Administration for two supplemental applications for Ibuprofen tablets [1] - The approved drug has passed the consistency evaluation of quality and efficacy for generic drugs [1]

Core Insights - China is demonstrating significant breakthroughs in technological innovation, characterized by three core advantages: industrial chain clusters, a surplus of STEM graduates, and a vast market scale that is difficult for other economies to replicate [1][6]. Industrial Chain Clusters - In regions like the Yangtze River Delta and the Pearl River Delta, thousands of suppliers and engineers are concentrated within a short distance, providing a competitive edge that countries like Mexico, India, and Southeast Asia lack [3][8]. - China graduates nearly 5 million STEM students annually, surpassing the combined total of Europe and the United States [3][8]. AI and Technology - Chinese companies are achieving technological catch-up in the AI sector with only 1/10 of the investment compared to the U.S., and they account for a significant portion of global AI talent [3][8]. - By 2027-2028, China is projected to achieve a 50% domestic production rate in GPU technology, marking a significant advancement [3][8]. Robotics and Automotive Industry - China holds a 60% share of the global leading companies in humanoid robotics, with a strong cost advantage in components like arms and hydraulic systems [4][9]. - It is estimated that 30% of the global increase in humanoid robot supply may come from China in the future [4][9]. Smart Driving and Biopharmaceuticals - China leads globally in smart driving adoption and is experiencing explosive growth in the biopharmaceutical sector [4][10]. - By 2040, it is projected that over one-third of new innovative drugs approved by the U.S. FDA will originate from China [4][10]. Traditional Industries and Export Market - China monopolizes the global refining and processing of rare earths and lithium batteries, continuously enhancing its industrial chain competitiveness [4][10]. - Currently, China accounts for approximately 14% of global exports, with projections suggesting this could rise to nearly 16% or higher in five years, potentially exceeding 17% [4][10]. - The three core advantages and innovations in emerging industries are expected to solidify China's position in the global export market [4][10].